{"id":185279,"name":"BLUEBIRD BIO","slug":"bluebird-bio","state":"MA","country":"United States of America","description":"Gene therapy company developing treatments for severe and incurable diseases.","totalSpending":280000,"filings":9,"yearlySpending":[{"year":2019,"income":20000},{"year":2020,"income":180000},{"year":2021,"income":80000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["POLSINELLI PC"],"lobbyists":["ALAN WHEAT"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Issues related to developing government structures to encourage gene therapy treatment in the patient population.","Provide guidance and strategic counsel with regard to regulations and legislation that could impact the gene therapies, drug pricing, and other issues that impact the industry generally, but bluebird ","Issues related to the reimbursement of gene therapies; issues related to the Patient Affordability and Efficiency Act.\nS. 2543, Prescription Drug Pricing Reduction Act; issues related to value-based p","Issues related to the reimbursement of gene therapies; issues related to the Patient Affordability and Efficiency Act.\nS. 2543, Prescription Drug Pricing Reduction Act; issues related to value-based p","Provide guidance and strategic counsel with regard to regulations and legislation that could impact the gene therapies, drug pricing, and other issues that impact the industry generally, but bluebird "]}